Significance of elevated preoperative α-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors

被引:16
作者
Kobayashi, Takashi [1 ]
Kawakita, Mutsushi [1 ]
Terachi, Toshiro [1 ]
Habuchi, Tomonori [1 ]
Ogawa, Osamu [1 ]
Kamoto, Toshiyuki [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, Kyoto 6068507, Japan
关键词
tumor marker; alpha-fetoprotein; metastatic testicular cancer; surgical treatment;
D O I
10.1002/jso.20418
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background and Objectives: The purpose of the study is to determine the significance of elevated serum a-fetoprotein (AFP) in the setting prior to residual tumor resection (RTR) following chemotherapy for metastatic germ cell tumor in terms of the prediction of histology of the specimen and postoperative survival. Methods: We conducted a retrospective review of 68 patients undergoing RTR for metastatic nonseminomatous germ cell tumor or extragonadal germ cell tumor after at least a first-line chemotherapy. Pretreatment and postchemotherapy serum markers were evaluated in association with other clinical findings including results of pathological examination of RTR specimen and surgical outcome. Results: Of the 68 study patients, 54 (79%) and 45 (66%) had positive AFP and beta-human chorionic gonadotropin (beta-HCG) in pretreatment settings. Rates of presence of residual malignant cell in RTR specimen were similar between patients with normal AFP (7/28 or 25%) and with mildly elevated (10-30 ng/ml) AFP (3/11 or 27%). In 26 patients who had residual viable malignancy in RTR specimen, patients with preoperative positive AFP had significantly better survival (P=0.02) compared to those with preoperative positive beta-HCG. Conclusions: Sole and mild elevation of AFP is not always associated with postoperative poor prognosis. It should be carefully considered individually whether a mild elevation of AFP after chemotherapy represents residual malignancy or benign pathogenesis.
引用
收藏
页码:619 / 623
页数:5
相关论文
共 35 条
[1]
PROGNOSTIC FACTORS IN UNSELECTED PATIENTS WITH NONSEMINOMATOUS METASTATIC TESTICULAR CANCER - A MULTICENTER EXPERIENCE [J].
AASS, N ;
KLEPP, O ;
CAVALLINSTAHL, E ;
DAHL, O ;
WICKLUND, H ;
UNSGAARD, B ;
BALDETORP, L ;
AHLSTROM, S ;
FOSSA, SD .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (05) :818-826
[2]
Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers [J].
Albers, P ;
Ganz, A ;
Hannig, E ;
Miersch, MDE ;
Müller, SC .
JOURNAL OF UROLOGY, 2000, 164 (02) :381-384
[3]
PROGNOSTIC FACTORS FOR FAVORABLE OUTCOME IN DISSEMINATED GERM-CELL TUMORS [J].
BIRCH, R ;
WILLIAMS, S ;
CONE, A ;
EINHORN, L ;
ROARK, P ;
TURNER, S ;
GRECO, FA .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (03) :400-407
[4]
Testicular germ-cell cancer [J].
Bosl, GJ ;
Motzer, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (04) :242-253
[5]
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma [J].
Collette, L ;
Sylvester, RJ ;
Stenning, SP ;
Fossa, SD ;
Mead, GM ;
de Wit, R ;
de Mulder, PHM ;
Neymark, N ;
Lallemand, E ;
Kaye, SB .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (10) :839-846
[6]
Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone [J].
Coogan, CL ;
Foster, RS ;
Rowland, RG ;
Bihrle, R ;
Smith, ER ;
Einhorn, LH ;
Roth, BJ ;
Donohue, JP .
UROLOGY, 1997, 50 (06) :957-962
[7]
PROBLEMS OF INTERPRETATION OF SERUM CONCENTRATIONS OF ALPHA-FETOPROTEIN (AFP) IN PATIENTS RECEIVING CYTO-TOXIC CHEMOTHERAPY FOR MALIGNANT GERM-CELL TUMORS [J].
COPPACK, S ;
NEWLANDS, ES ;
DENT, J ;
MITCHELL, H ;
GOKA, G ;
BAGSHAWE, KD .
BRITISH JOURNAL OF CANCER, 1983, 48 (03) :335-340
[8]
Donohue J P, 1998, Semin Urol Oncol, V16, P65
[9]
CYTOREDUCTIVE SURGERY FOR METASTATIC TESTIS CANCER - CONSIDERATIONS OF TIMING AND EXTENT [J].
DONOHUE, JP ;
EINHORN, LH ;
WILLIAMS, SD .
JOURNAL OF UROLOGY, 1980, 123 (06) :876-880
[10]
SURGICAL RESECTION IN PATIENTS WITH NONSEMINOMATOUS GERM-CELL TUMOR WHO FAIL TO NORMALIZE SERUM TUMOR-MARKERS AFTER CHEMOTHERAPY [J].
EASTHAM, JA ;
WILSON, TG ;
RUSSELL, C ;
AHLERING, TE ;
SKINNER, DG .
UROLOGY, 1994, 43 (01) :74-80